Data

A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide (EC) followed by docetaxel with gemcitabine (DG) (+trastuzumab if HER2-positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma (ANZ 0502 NeoGem)

Health Data Australia Contributor Records
Breast Cancer Trials (BCT) ; A/Prof Nicole McCarthy, A/Prof Nicole McCarthy ; Breast Cancer Trials (BCT)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58080/456K-N112&rft.title=A phase II trial evaluating the efficacy and safety of epirubicin and cyclophosphamide (EC) followed by docetaxel with gemcitabine (DG) (+trastuzumab if HER2-positive) as neoadjuvant chemotherapy for women with large operable or locally advanced breast carcinoma (ANZ 0502 NeoGem)&rft.identifier=http://doi.org/10.58080/456K-N112&rft.publisher=Breast Cancer Trials (BCT)&rft.description=* Dataset of 134 women with ER-positive, HER2-negative grade 2/3 invasive breast cancer > 20mm * Randomised 2:1 to receive either standard neoadjuvant chemotherapy concurrently with aromatase inhibitor (89 patients) or standard neoadjuvant chemotherapy only (45 patients)for 18-24 weeks * Rate of downstaging to pathologic stage 0 or 1A, pCR at time of surgery data * Median breast tumour volume percentage decrease, rate of breast conserving surgery, SAE rates data&rft.creator=Breast Cancer Trials (BCT) &rft.creator=A/Prof Nicole McCarthy, A/Prof Nicole McCarthy &rft.creator=Breast Cancer Trials (BCT) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12606000191594&rft_subject=Chemotherapy&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

* Dataset of 134 women with ER-positive, HER2-negative grade 2/3 invasive breast cancer > 20mm * Randomised 2:1 to receive either standard neoadjuvant chemotherapy concurrently with aromatase inhibitor (89 patients) or standard neoadjuvant chemotherapy only (45 patients)for 18-24 weeks * Rate of downstaging to pathologic stage 0 or 1A, pCR at time of surgery data * Median breast tumour volume percentage decrease, rate of breast conserving surgery, SAE rates data

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Organisations

Subjects
Chemotherapy |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Breast Cancer Trials (BCT)

ROR : https://ror.org/00j1vsg87

Identifiers
Similar data you may be interested in: